Vesalius Cardiovascular Announces the Completion of a Successful Chronic Animal Study

VANCOUVER, British Columbia, January 21, 2020 (Newswire.com) Vesalius Cardiovascular Inc. (VCI), a pre-clinical stage medical device company developing novel percutaneous therapies for the treatment of mitral regurgitation, today announced the successful completion of their first 30-day chronic animal study using their mitral valve repair device. The predetermined endpoints of the study were the absence of […]